partnerStalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01Latest NewsPrecision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. Read more 12 October 2022 https://european-biotechnology.com/wp-content/uploads/2024/04/Stalicla_CEO_Lynn_Durham.jpg 200 200 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2022-10-12 11:15:282024-07-16 12:41:50Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01